Showing results (91-100 of 314) with videos related to

Sort By:
Pageof 32
Clinical Reviews in Allergy & Immunology|September 1, 2005
Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspectsJosef S Smolen, Kurt Redlich, Jochen Zwerina, et al.
Seminars in Arthritis and Rheumatism|October 9, 2019
Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remissionDaniel Aletaha, Xin Wang, Sheng Zhong, et al.
The Journal of Rheumatology|April 3, 2016
Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics TrialsMaarten Boers, Daniel Aletaha, Christopher M Mela, et al.
AJR. American Journal of Roentgenology|January 24, 2007
Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitisClaudia Schueller-Weidekamm, Christian Krestan, Gerd Schueller, et al.
Advances in Therapy|May 19, 2019
Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort StudyDaniel Aletaha, Andrew J Epstein, Martha Skup, et al.
Rheumatology (Oxford, England)|July 11, 2009
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritisNathan Vastesaeger, Stephen Xu, Daniel Aletaha, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 18, 2017
Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patientsDaniel Aletaha, Sonya J Snedecor, Varun Ektare, et al.
Arthritis Research & Therapy|June 19, 2008
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Josef S Smolen, Daniel Aletaha, Johannes Grisar, et al.
Rheumatology (Oxford, England)|October 9, 2009
Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patientsMarcus D Köller, Daniel Aletaha, Julia Funovits, et al.
Annals of the Rheumatic Diseases|February 23, 2022
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritisPedro Lopez-Romero, Inmaculada de la Torre, Ewa Haladyj, et al.
Pageof 32